Cantor Fitzgerald Weighs in on RIGL FY2026 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Rigel Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will post earnings per share of $1.05 for the year. Cantor Fitzgerald has a "Neutral" rating and a $23.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $0.22 per share.

Several other equities analysts have also issued reports on RIGL. HC Wainwright reaffirmed a "buy" rating and issued a $57.00 target price on shares of Rigel Pharmaceuticals in a report on Wednesday, March 5th. Wall Street Zen cut Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 8th. Citigroup raised their price objective on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, B. Riley lifted their price objective on shares of Rigel Pharmaceuticals from $20.00 to $24.00 and gave the stock a "neutral" rating in a research report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $36.40.

Rigel Pharmaceuticals Trading Up 0.5%

Shares of NASDAQ:RIGL traded up $0.11 during mid-day trading on Tuesday, hitting $21.30. 110,813 shares of the company traded hands, compared to its average volume of 219,642. The stock has a 50-day moving average price of $18.84 and a two-hundred day moving average price of $19.86. Rigel Pharmaceuticals has a 12-month low of $7.48 and a 12-month high of $29.82. The stock has a market cap of $380.67 million, a P/E ratio of 152.15 and a beta of 1.29.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.49. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. The company had revenue of $53.33 million for the quarter, compared to analysts' expectations of $43.87 million. During the same quarter in the prior year, the firm earned ($0.50) EPS.

Hedge Funds Weigh In On Rigel Pharmaceuticals

A number of institutional investors have recently bought and sold shares of RIGL. Virtus Advisers LLC bought a new stake in Rigel Pharmaceuticals during the 1st quarter valued at approximately $40,000. US Bancorp DE lifted its holdings in shares of Rigel Pharmaceuticals by 57.4% in the 1st quarter. US Bancorp DE now owns 5,120 shares of the biotechnology company's stock worth $92,000 after acquiring an additional 1,868 shares during the last quarter. New York State Common Retirement Fund grew its position in Rigel Pharmaceuticals by 65.9% in the 1st quarter. New York State Common Retirement Fund now owns 5,536 shares of the biotechnology company's stock valued at $100,000 after acquiring an additional 2,200 shares during the last quarter. Wells Fargo & Company MN grew its stake in Rigel Pharmaceuticals by 44.5% in the 4th quarter. Wells Fargo & Company MN now owns 8,603 shares of the biotechnology company's stock worth $145,000 after acquiring an additional 2,648 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in Rigel Pharmaceuticals by 42.8% during the 4th quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company's stock worth $159,000 after purchasing an additional 2,827 shares during the period. 66.23% of the stock is owned by institutional investors.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.